Jubilant Pharmo
Drug Manufacturers - Specialty & Generic · JUBLPHARMA
Mid CapHealthcareDistressed / Turnaround
Priyavrat Bhartia
Managing Director · Pragmatic
Company DNA
Hierarchical
About
Jubilant Pharmo is a Mid Cap company in the Healthcare sector, listed on NSE as JUBLPHARMA. With a market cap of ₹13K Cr and revenue of ₹7K Cr, it is currently in the Distressed / Turnaround phase. Known for its Hierarchical culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Part of a large, long-standing conglomerate; culture reflects established formal structures and complex manufacturing processes. Its strategic mandate: Requires urgent deleveraging and asset optimization to stabilize the balance sheet and improve operating margins.
FAQ
What kind of company is Jubilant Pharmo?
Jubilant Pharmo is a Mid Cap Healthcare company (JUBLPHARMA) in the Distressed / Turnaround phase with a market cap of ₹13K Cr. It is classified as Hierarchical in culture.
What is Jubilant Pharmo's culture and work environment like?
Jubilant Pharmo has a Hierarchical culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. Part of a large, long-standing conglomerate; culture reflects established formal structures and complex manufacturing processes.
Who leads Jubilant Pharmo?
Jubilant Pharmo is led by Priyavrat Bhartia (Managing Director), a Pragmatic leader with 22 years of experience.
What are Jubilant Pharmo's financials?
Jubilant Pharmo reported revenue of ₹7K Cr in FY25 with a 5-year revenue CAGR of 5.9%. Operating margin: 11.2%. Market cap: ₹13K Cr.
Culture & Strategy
CultureHierarchical
InnovationFast-Follower
PaceSteady-Marathon
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandTechnical-Expert
LifecycleDistressed / Turnaround
Part of a large, long-standing conglomerate; culture reflects established formal structures and complex manufacturing processes.
Mandate
Requires urgent deleveraging and asset optimization to stabilize the balance sheet and improve operating margins.
Requires urgent deleveraging and asset optimization to stabilize the balance sheet and improve operating margins.
Financials
Revenue FY25₹7K Cr
PAT FY25₹839 Cr
Rev CAGR 5Y5.9%
OPM11.2%
NPM11.7%
ROE13.4%
ROCE7.6%
P/E31
Fwd P/E23.3
P/B2
D/E43.9
Mkt Cap₹13K Cr
Promoter58%
Institutional21.2%
Similar Culture
Could You Lead Jubilant Pharmo?
Take the Genome Benchmark →